23:34 , Sep 14, 2017 |  BC Innovations  |  Strategy

Qrating assets

Launched in July, Qrativ Holdings LLC is the latest venture to apply artificial intelligence to drug development, carving out a new niche by using AI to find uses for discarded early stage compounds, rather than...
08:00 , Feb 18, 2016 |  BC Innovations  |  Emerging Company Profile

A need for speed

Bioinformatics play twoXAR Inc. aims to condense years of wet-lab compound discovery and lead prioritization into minutes. The company has created an in silico platform that uses machine learning to build a mathematical disease model...
07:00 , Aug 6, 2015 |  BC Innovations  |  Tools & Techniques

Silicon Flexibility

While companies and academics are chasing proteomics to find new targets for drug discovery, Cyclica Inc. thinks the field is limited by the fact that most of the data derive from static 3D crystal structures...
07:00 , Oct 31, 2013 |  BC Innovations  |  Targets & Mechanisms

Benztropine for MS

Although the secondary progressive multiple sclerosis space is filling up with new compounds, few have shown the ability to remyelinate neurons. A new study suggests that an ancient Parkinson's disease drug-benztropine-could accomplish that task in...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Company News

Biovista, Dart Therapeutics deal

Biovista will use its Clinical Outcome Search Space (COSS) technology to identify which of Dart's existing compounds may be used to treat Duchenne muscular dystrophy (DMD). Dart will have the option to select an undisclosed...
07:00 , Oct 25, 2012 |  BC Innovations  |  Targets & Mechanisms

Myelination from neural stem cells

University of California, San Francisco , Oregon Health & Science University and StemCells Inc. have found that neural stem cell transplants could remyelinate axons and treat myelination disorders including Pelizaeus-Merzbacher disease. 1,2 The biotech is...
08:00 , Mar 5, 2012 |  BioCentury  |  Product Development

Mining for safety mechanisms

FDA has been quietly test-driving informatics platforms that include mechanism of action data to complement and augment the agency's safety surveillance techniques. Most recently, FDA began evaluating MolecularHealth Inc. 's Molecular Analysis of Side Effects...
07:00 , May 2, 2011 |  BC Week In Review  |  Company News

Biovista, Novartis deal

Biovista will use its Clinical Outcome Search Space (COSS) technology to identify new indications for undisclosed Novartis compounds. Biovista will receive an upfront payment and is eligible for milestones. Further terms were not disclosed. Biovista...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Company News

Biovista, Pfizer deal

Biovista and Pfizer's Indications Discovery Unit will use Biovista's Clinical Outcome Search Space (COSS) technology to identify up to three new indications for undisclosed Pfizer drug candidates. The COSS technology focuses on mechanism of action-based...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Clinical News

Biovista preclinical data

In an experimental allergic encephalomyelitis (EAE) murine model of MS, BVA-201 significantly reduced the severity of EAE from baseline, the magnitude of which was comparable to dexamethasone. BVA-201 also protected neural axons and myelin from...